QuidelOrtho (NASDAQ:QDEL) Releases Quarterly Earnings Results, Misses Estimates By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL) issued its earnings results on Wednesday. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Stock Down 3.7 %

QDEL opened at $39.94 on Thursday. The company has a market cap of $2.69 billion, a PE ratio of -1.43 and a beta of 0.08. The company has a 50-day moving average price of $43.28 and a 200 day moving average price of $42.36. QuidelOrtho has a twelve month low of $29.74 and a twelve month high of $68.85. The company has a quick ratio of 0.81, a current ratio of 1.38 and a debt-to-equity ratio of 0.68.

Wall Street Analyst Weigh In

QDEL has been the topic of several recent research reports. Jefferies Financial Group assumed coverage on QuidelOrtho in a research report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 price objective on the stock. StockNews.com raised shares of QuidelOrtho from a “hold” rating to a “buy” rating in a report on Friday, February 7th. William Blair reaffirmed a “market perform” rating on shares of QuidelOrtho in a report on Wednesday, November 20th. Finally, Citigroup raised shares of QuidelOrtho from a “neutral” rating to a “buy” rating and increased their target price for the stock from $44.00 to $50.00 in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, QuidelOrtho presently has a consensus rating of “Hold” and an average target price of $53.43.

Insider Transactions at QuidelOrtho

In other QuidelOrtho news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $35.31, for a total value of $291,667,061.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian J. Blaser bought 6,033 shares of the stock in a transaction dated Wednesday, December 11th. The shares were bought at an average price of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the acquisition, the chief executive officer now owns 6,033 shares in the company, valued at approximately $249,886.86. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.